Crohn’s disease Epidemiology Forecast to 2026 report provides an overview of global and historical trends for Crohn’s Disease Epidemiology in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan), Risk factors and Forecasts 2026.
Crohn’s disease (CD) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. While any part of the gastrointestinal tract can be affected, inflammation is most commonly found at the end of the small intestine (ileum), and the start of the large intestine (colon).
The disease course of Crohn’s Disease Epidemiology (CD) is characterized by periods of remission followed by periods of relapse, the length and severity of which differ from case to case (CDC, 2014; NHS, 2015). Inflammation in CD can result in severe scarring and narrowing of parts of the bowel.
There is no cure for CD, and treatment aims to control symptoms and sustain remission; it is estimated that up to three quarters of those with CD require surgery (CCFA, 2017; NHS, 2015).
Crohn’s disease (CD) report provides an overview of the risk factors, comorbidities, and global and historical trends for Crohn’s Disease Epidemiology in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of CD in these markets.
The diagnosed prevalent cases of CD are further segmented by sex and age in these markets. The diagnosed prevalent cases are further segmented by severity (mild to moderate, moderate to severe, and severe to fulminant) and by comorbid autoimmune diseases (psoriasis, ankylosing spondylitis, and pyodermagangrenosum).
Furthermore, an alternate forecast of diagnosed incident and diagnosed prevalent cases of Crohn’s Disease - Epidemiology is provided for markets where there was insufficient data to trend in the main forecast, to estimate the patient size if trending was applied. For incident cases the alternate forecast includes the US and 5EU (France, Germany, Italy, Spain, and UK), and for prevalent cases the alternate forecast includes Germany, Italy, Spain, and the UK.
GlobalData epidemiologists forecast that the diagnosed incident cases of CD in the 7MM will increase from 70,985 in 2016 to 74,712 in 2026 at an Annual Growth Rate (AGR) of 0.53%. The US will have the highest number of diagnosed incident cases of CD in both 2016 and 2026 at 44,886 and 47,477, respectively.